IRWD Stock Overview
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products.
Ironwood Pharmaceuticals, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$11.91|
|52 Week High||US$12.95|
|52 Week Low||US$9.73|
|1 Month Change||1.28%|
|3 Month Change||8.57%|
|1 Year Change||4.11%|
|3 Year Change||-3.87%|
|5 Year Change||-23.41%|
|Change since IPO||2.23%|
Recent News & Updates
These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt SafelySep 28
Here's Why I Think Ironwood Pharmaceuticals (NASDAQ:IRWD) Might Deserve Your Attention TodayJul 21
Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More DebtJun 22
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is LackingMar 25
Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More DebtMar 04
A Look At Ironwood Pharmaceuticals' (NASDAQ:IRWD) Share Price ReturnsFeb 06
|IRWD||US Biotechs||US Market|
Return vs Industry: IRWD exceeded the US Biotechs industry which returned -11.2% over the past year.
Return vs Market: IRWD exceeded the US Market which returned -20.6% over the past year.
|IRWD Average Weekly Movement||3.9%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: IRWD is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: IRWD's weekly volatility (4%) has been stable over the past year.
About the Company
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis.
Ironwood Pharmaceuticals, Inc. Fundamentals Summary
|IRWD fundamental statistics|
Is IRWD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IRWD income statement (TTM)|
|Cost of Revenue||US$70.38m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||1.09|
|Net Profit Margin||39.85%|
How did IRWD perform over the long term?See historical performance and comparison